Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ProstAtak as Adjuvant to Radiation Therapy for Localized Prostate Cancer
NCT01436968Phase 3Active, not recruiting
- Sponsor
- Candel Therapeutics
- Start
- Sep 2011
- Primary completion
- Aug 2024
- Countries
- 2
01
Overview
A Phase 3 trial of aglatimagene besadenovec in prostate cancer (PCa), sponsored by Candel Therapeutics. Started Sep 2011; status: active, not recruiting.
02
Drugs
aglatimagene besadenovec
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT01436968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01436968.